Tipiracil
Highest phase reached
Approved
Drug type
Small molecule
First approval year
2015
- First approval year
- 2015
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Tipiracil
- Molecular weight
- 242.67
- Structure (SMILES)
- N=C1CCCN1Cc1[nH]c(=O)[nH]c(=O)c1Cl
- 5 chloro 6 2 iminopyrrolidin 1 yl methyl pyrimidine 2 4 1h 3h dione
- 5-Chloro-6-[(2-iminopyrrolidin-1-yl)methyl]pyrimidine-2,4-(1H,3H)-dione
- GSK1322322 (freebase) tablets FED
- gsk1322322 freebase tablets fed
- ma 1
- MA-1
- tipiracil
- Tipiracil
- tipiracil [INN]
- TIPIRACIL [MI]
- TIPIRACIL [USAN]
- Tipiracil [WHO-DD]
- tipiracil ftd tpi
- tipiracil inn
- tipiracil mi
- tipiracil usan
- tipiracil who dd
- tipiracil( FTD/TPI)
- tipiracilo
- Tipiracilo
- tpi
- TPI
- TPI (freebase)
- tpi freebase
- CAS registry numbers
- 183204-74-2
- ChEMBL ID
- CHEMBL235668
- InChIKey
- QQHMKNYGKVVGCZ-UHFFFAOYSA-N
- PubChem compound IDs
- 6323266
- FDA ingredient codes (UNII)
- NGO10K751P
- 1670303
- 1670304
- Applicant
- TAIHO ONCOLOGY
- Approval date
- 22 Sept 2015
- Application number
- NDA207981
- First in class
- No
- Orphan designation
- No
- Availability
- Prescription only
- United States (FDA)
- Approved
- Pharmacology name
- tipiracil
- Type
- Synthetic organic
- Drug name stem
- -racil
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
Open Targets mechanisms
- Mechanism
- Thymidine phosphorylase inhibitor
- Action type
- Inhibitor
- Target
- Thymidine phosphorylase
DrugCentral mechanisms
- Action type
- Inhibitor
- Gene symbol
- TYMP
- Protein identifier
- P19971
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Stomach Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000503
- Subject identifier
- D013274
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Carcinoma, Non-Small-Cell Lung
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003060
- Subject identifier
- D002289
- Condition
- Breast Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003869
- Subject identifier
- D001943
- Condition
- Colorectal Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004142
- Subject identifier
- D015179
- Condition
- Cholangiocarcinoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0005221
- Subject identifier
- D018281
- Condition
- Pancreatic Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:1000359
- Subject identifier
- D010190
- Condition
- Rectal Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:1000657
- Subject identifier
- D012004
- Condition
- Colonic Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:1001950
- Subject identifier
- D003110
- Condition
- Stomach Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0001056
- Subject identifier
- D013274
- Condition
- Urinary Bladder Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0001187
- Subject identifier
- D001749
- Condition
- Colorectal Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0005575
- Subject identifier
- D015179
- Condition
- Breast Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0007254
- Subject identifier
- D001943
- Condition identifier
- EFO_0000616
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003869
- Highest recorded phase
- 2
- Condition identifier
- EFO_0004142
- Condition identifier
- EFO_0005221
- Highest recorded phase
- 2
- Condition identifier
- EFO_1000359
- Highest recorded phase
- 2
- Condition identifier
- EFO_1000657
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001480
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001480
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0001056
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0001187
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002032
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002169
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0002271
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0003060
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0003219
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0003220
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0004970
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005008
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005028
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005036
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005335
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005575
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005575
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005580
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0006047
- Highest recorded phase
- 2
And 10 more, listed on the interactive page.
- Event
- abdominal pain
- Reports
- 149
- Reporting signal score
- 78.8027
- Event
- abdominal pain upper
- Reports
- 82
- Reporting signal score
- 37.1123
- Event
- alopecia
- Reports
- 95
- Reporting signal score
- 73.2123
- Event
- anaemia
- Reports
- 143
- Reporting signal score
- 69.2157
- Event
- asthenia
- Reports
- 134
- Reporting signal score
- 36.3192
- Event
- blood alkaline phosphatase abnormal
- Reports
- 13
- Reporting signal score
- 43.242
- Event
- blood count abnormal
- Reports
- 42
- Reporting signal score
- 66.1893
- Event
- carcinoembryonic antigen increased
- Reports
- 18
- Reporting signal score
- 52.1183
- Event
- colorectal cancer metastatic
- Reports
- 16
- Reporting signal score
- 49.9845
- Event
- constipation
- Reports
- 104
- Reporting signal score
- 51.8902
- Event
- cytopenia
- Reports
- 50
- Reporting signal score
- 105.327
- Event
- decreased appetite
- Reports
- 247
- Reporting signal score
- 302.372
- Event
- diarrhoea
- Reports
- 430
- Reporting signal score
- 299.132
- Event
- dilated cardiomyopathy
- Reports
- 1
- Reporting signal score
- 7.93746
- Event
- disease progression
- Reports
- 524
- Reporting signal score
- 1,262.23
- Event
- drug hypersensitivity
- Reports
- 1
- Reporting signal score
- 46.2707
- Event
- dysgeusia
- Reports
- 62
- Reporting signal score
- 62.1491
- Event
- fatigue
- Reports
- 553
- Reporting signal score
- 470.637
- Event
- febrile neutropenia
- Reports
- 3
- Reporting signal score
- 9.42069
- Event
- gastrointestinal toxicity
- Reports
- 2
- Reporting signal score
- 10.6331
- Event
- horner's syndrome
- Reports
- 1
- Reporting signal score
- 6.67823
- Event
- intestinal obstruction
- Reports
- 52
- Reporting signal score
- 68.5577
- Event
- malignant neoplasm progression
- Reports
- 72
- Reporting signal score
- 63.0344
- Event
- mucosal toxicity
- Reports
- 1
- Reporting signal score
- 7.16076
- Event
- nausea
- Reports
- 486
- Reporting signal score
- 310.021
And 7 more, listed on the interactive page.
- NCT03520946
- NCT03799731
- NCT05029882
- NCT05077839
- NCT05198934
- NCT06379399
- NCT03762161
- NCT04076761
- NCT04149444
- NCT04393298
- NCT04417699
- NCT05965531
- NCT04457297
- NCT04489173
- NCT04923529
- NCT05029102
- NCT05062889
- NCT05927857
- Dose
- 35 mg/m2
- Route
- Oral
- How often
- Twice daily on Days 1-5 and 8-12 of each 28-day cycle
- Swallow tablets whole
- Take with food
- Hydrogen bond acceptors
- 3
- Hydrogen bond donors
- 3
- Polar surface area
- 92.81
- Calculated partition coefficient (ALogP)
- 0.29
- Calculated partition coefficient (XLogP)
- -0.7
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 2
- Heavy atoms
- 16
- Molecular formula
- C9H11ClN4O2
- Monoisotopic mass
- 242.0570533
- Natural product
- Yes
- Recorded assays
- 121
- Active assays
- 11
Active assay types
- Confirmatory
Related records
Trials (83)
- - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases
- 5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer
- A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs
- A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer
- A Prospective, Single-arm, Exploratory Study of Trifluridine/Tipiracil (TAS-102) Combined With Apatinib as Third-line Therapy for Advanced Gastric Cancer
- A Real-world Study of Trifluridine/Tipiracil Containing Regimen for the Treatment of Patients With mCRC (REFLECT Study)
- A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab
- A Study of ASP1002 in Adults for Treatment of Solid Tumors
- A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
- A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer
- A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
- A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC)
- A Study of Trifluridine/ Tipiracil in Chemorefractory mCRC in Greece
- A Study of Trifluridine/Tipiracil in Triple Negative Metastatic Breast Cancer
- A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
- A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors
- A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)
- A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations
- A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
- An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions
In development for (30)
- Adenocarcinoma Phase 2
- Biliary tract cancer Phase 2
- Breast cancer Phase 2
- Breast neoplasm Phase 2
- Cholangiocarcinoma Phase 2
- Colon adenocarcinoma Phase 1
- Colon carcinoma Phase 2
- Colorectal adenocarcinoma Phase 2
- Colorectal cancer Phase 3
- Colorectal carcinoma Phase 2
- Colorectal neoplasm Phase 3
- Digestive system neoplasm Phase 1
- Esophageal adenocarcinoma Phase 2
- Esophageal cancer Phase 2
- Esophageal squamous cell carcinoma Phase 2
- Gallbladder carcinoma Phase 2
- Gastric adenocarcinoma Phase 2
- Gastric cancer Phase 2
- Gastric neoplasm Phase 2
- Gastroesophageal junction adenocarcinoma Phase 2
Targets (1)
- TYMP Thymidine phosphorylase inhibitor